Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 27, 2007

King Pharmaceuticals Procures Avinza from Ligand for $295M

  • King Pharmaceuticals closed its asset purchase agreement with Ligand Pharmaceuticals under which King has acquired the pain medication Avinza® (morphine sulfate extended-release).

    Avinza is indicated as a once-daily morphine treatment for chronic, moderate-to-severe pain in patients who require continuous, around-the-clock opioid therapy for an extended period of time, including osteoarthritis, back pain, musculoskeletal conditions, cancer, and neuropathic pain.

    Under the terms of the agreement, King has made a $246 million payment to Ligand to acquire all the rights to Avinza in the United States and Canada. In addition, King has reimbursed Ligand for certain product-related liabilities and other expenses totaling $49 million and has assumed all existing product royalty obligations.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »